Skip to main content

Receives a new patent in the EU

VibroSense Dynamics AB has received a so-called "Intention To Grant" on its patent application in the EU, which strengthens the protection for the product VibroSense Meter® II. The patent describes a principle for measuring skin temperature wirelessly before and during an examination, which ensures measurement quality.

The patent was approved in Sweden in November 2020 and in April in China, and after an international application, the company has now been informed that the patent will be approved in the EU. After that, a process for national applications begins throughout the EU. The company also has an active application for the current patent in USA.

"We have chosen to protect our VibroSense Meter II product on several levels. The highest level consists of patents and designs protection where the strategy is to prevent infringement of essential functions for the instrument's measuring principle. At lower levels, the protections have been designed in the form of encrypted algorithms in the software, which together with the patents give the product strong protection. A new patent to protect our continuous temperature measurement further strengthens the protection of our product", says Toni Speidel, CTO VibroSense Dynamics AB.

Contact
Toni Speidel, CTO VibroSense Dynamics AB
Tel: +46 40 88 026
Email: info@vibrosense.com
www.vibrosense.com

"The new Gold Standard for reliable
detection of nerve damage"

About VibroSense Dynamics AB (publ)
VibroSense Dynamics AB (publ) develops and sells medical technology products to facilitate diagnosis of peripheral nerve damage in the hands and feet. The method involves measuring and quantifying the ability to perceive vibrations at several frequencies. The company's customers are diabetes clinics, occupational health care, hospitals, point of care centers and researchers.

Our vision is for the company's products to be a standard instrument in all neurological examinations to detect early signs of changes in sensation so that patients and their caregivers can implement preventive measures that prevent, reduce or delay the onset of nerve damage in the hands and feet.